Experience with PRRT by Site of Primary Tumor
| Author | Year | Patients* | Treatment | ORR | PFS | OS |
| Midgut NETs (grade 9) | ||||||
| Strosberg (7) | 2017 | 116 | 177Lu-DOTATATE | 18%, 18/101 | NR | NR |
| Sabet (3) | 2015 | 61 | 177Lu-DOTATATE | 13%, 8/61 | 33 | 61 |
| Hörsch (5) | 2016 | 138 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 51 | NR |
| Brabander (4) | 2017 | 181 | 177Lu-DOTATATE | 31%, 57/181 | 30 | 60 |
| Baum (6) | 2018 | 315 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 22 | 69 |
| Pancreatic NETs (grade 8) | ||||||
| Baum (6) | 2018 | 315 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 20 | 44 |
| Hörsch (5) | 2016 | 172 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 39 | 53 |
| Brabander (4) | 2017 | 133 | 177Lu-DOTATATE | 55%, 72/133 | 30 | 71 |
| Ezziddin (10) | 2014 | 68 | 177Lu-DOTATATE | 60%, 41/68 | 34 | 53 |
| Sansovini (53) | 2017 | 60 | 177Lu-DOTATATE | 30%, 18/60 | 29 | NR |
| Garske-Román (9) | 2018 | 48 | 177Lu-DOTATATE | 45%, 22/49 | NR | NR |
| Bronchial carcinoid (before everolimus grade 6; after everolimus grade 7) | ||||||
| Mariniello (54) | 2016 | 114 | 177Lu-DOTATATE 90Y-DOTATOC | 13%, 15/114 | 28 | 59 |
| Baum (6) | 2018 | 75 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 11 | 40 |
| Ianniello (55) | 2017 | 34 | 177Lu-DOTATATE | 15%, 4/32 | 19 | 49 |
| Brabander (4) | 2017 | 23 | 177Lu-DOTATATE | 30%, 7/23 | 20 | 52 |
| Parghane (56) | 2017 | 22 | 177Lu-DOTATATE | 11%, 2/19 | NR | 40 |
| Sabet (57) | 2017 | 22 | 177Lu-DOTATATE | 27%, 6/22 | 27 | 42 |
| Unknown primary tumor (grade 8) | ||||||
| Baum (6) | 2018 | 151 | 177Lu-DOTATATE 90Y-DOTATOC | NR | 13 | 53 |
| Brabander (4) | 2017 | 82 | 177Lu-DOTATATE | 35% 29/82 | 29 | 53 |
| Delpassand (58) | 2014 | 7 | 177Lu-DOTATATE | NR | 11 | NR |
| Bodei (11) | 2011 | 3 | 177Lu-DOTATATE | 0% 0/3 | NR | NR |
| Paraganglioma/pheochromocytoma (MIBG positive grade 5; MIBG negative grade 7) | ||||||
| Forrer (17) | 2008 | 28 | 177Lu-DOTATATE 90Y-DOTATOC | 7%, 2/28 | NR | NR |
| Kong (18) | 2017 | 20 | 177Lu-DOTATATE | 29%, 5/17 | 39 | NR |
| van Essen (16) | 2006 | 12 | 177Lu-DOTATATE | 17%, 2/12 | NR | NR |
↵* Only within NET subtype (n).
ORR = overall response rate; PFS = progression free survival (in months); OS = overall survival (in months); NR = not reported/reached.